Small interfering RNA

Nucleic Acid Based Gene Therapy Global Market Opportunities and Strategies to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 4, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Cell, Transgene, CAGR, Conditional sentence, Protagonist, Degenerative disease, Synthetic biology, Growth, Coronavirus, RNA interference, Research, Hospital, Nucleotide, Cancer, Prevalence, L-Ribonucleic acid aptamer, Technology, Small interfering RNA, Fine chemical, Healthcare

The "Nucleic Acid Based Gene Therapy Global Market Opportunities And Strategies To 2030, By Nucleic Acid Technology, Application, End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nucleic Acid Based Gene Therapy Global Market Opportunities And Strategies To 2030, By Nucleic Acid Technology, Application, End User" report has been added to ResearchAndMarkets.com's offering.
  • The global nucleic acid-based gene therapy market grew from $1,391.9 million in 2015 to $4,726.8 million in 2020 at a compound annual growth rate (CAGR) of 27.7%.
  • The nucleic acid-based gene therapy market is segmented by technology into anti-sense and anti-gene oligonucleotides, SiRNA and RNA Interference, gene transfer therapy, ribozymes, aptamers, and others.
  • North America was the largest region in the global nucleic acid-based gene therapy market, accounting for 46.2% of the total in 2020.

The Oligonucleotide Therapeutics Society Presents the 2021 Virtual Conference

Retrieved on: 
Saturday, September 4, 2021
Nucleic acids, Branches of biology, Biology, RNA, Molecular biology, Small interfering RNA, Silence Therapeutics, RNA interference, Alnylam Pharmaceuticals, Sense, Intellia Therapeutics

SAN DIEGO, Sept. 04, 2021 (GLOBE NEWSWIRE) -- The Oligo Meeting is purposefully designed to bring people together to share incredible advancements in the field of oligonucleotide therapeutics.

Key Points: 
  • SAN DIEGO, Sept. 04, 2021 (GLOBE NEWSWIRE) -- The Oligo Meeting is purposefully designed to bring people together to share incredible advancements in the field of oligonucleotide therapeutics.
  • Last year's virtual meeting was extraordinarily successful, and this year's virtual conference has been carefully planned to be even more seamlessly engaging and productive.
  • Recorded talks and posters can be viewed on-demand through December 31, 2021, for all registered delegates.
  • Last year's virtual conference received rave reviews from participants and this year's virtual meeting is expected to be even more spectacular.

OliX Pharmaceuticals Announces Results from Preclinical Study of NASH Therapeutic Candidate

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, RNA, Biology, Biochemistry, Gene expression, Molecular biology, Small interfering RNA, RNA interference, N-Acetylgalactosamine

SUWON, Republic of Korea, Aug. 04, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today presented preclinical data on OLX702A, an investigational therapeutic for the treatment of nonalcoholic steatohepatitis (NASH), at the 48th Korean Academy of Science and Technology (KAST) International Symposium. In the study, OLX702A reversed tissue damage in the liver in a mouse model of NASH.

Key Points: 
  • In the study, OLX702A reversed tissue damage in the liver in a mouse model of NASH.
  • OLX702A is a GalNAc-conjugated asymmetric siRNA (asiRNA) that targets a novel gene which is validated as a NASH-related target based on a genome-wide association study (GWAS).
  • We look forward to progressing development of OLX702A based on these encouraging preclinical data, said Dong Ki Lee, Ph.D., founder and chief executive officer of OliX Pharmaceuticals.
  • OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues

Retrieved on: 
Thursday, July 29, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Other Health, Branches of biology, RNA, Biology, Life sciences, Molecular biology, Gene expression, Small interfering RNA, Molecular genetics, Alnylam Pharmaceuticals, RNA interference, RNAi, Alnylam Pharmaceuticals, PeptiDream, Inc., RNAI, ALNYLAM PHARMACEUTICALS, PEPTIDREAM, INC.

Alnylam will then generate peptide-siRNA conjugates and perform in vitro and in vivo studies to support final peptide selection.

Key Points: 
  • Alnylam will then generate peptide-siRNA conjugates and perform in vitro and in vivo studies to support final peptide selection.
  • The collaboration has the potential to yield multiple treatment opportunities by targeting disease causing mRNA transcripts in a wide variety of tissue types.
  • Through this collaboration, we hope to identify robust ligand-receptor pairs for extrahepatic tissue delivery, similar to the GalNAc-ASGPR pair that we have pioneered for effective liver delivery.
  • Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform.

Crossing Blood-Brain Barrier: Delivery of Biomolecules into Glioblastoma Enabled by Altogen's Nanoparticle In Vivo Transfection Reagent

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Biology, Molecular biology, Life sciences, Biotechnology, Gene delivery, RNA, Laboratory techniques, Transfection, Small interfering RNA, Electroporation, Lipofectamine

In 2018 Altogen Biosystems launched the AltoFect transfection reagent formulated for difficult-to-transfect cells (like B-cells, T-cells), and primary cell cultures that are known to be resistant to most typical transfection technologies.

Key Points: 
  • In 2018 Altogen Biosystems launched the AltoFect transfection reagent formulated for difficult-to-transfect cells (like B-cells, T-cells), and primary cell cultures that are known to be resistant to most typical transfection technologies.
  • Company offers over 120 cell-line specific transfection kits, optimized electroporation products, and in vivo transfection reagents that are used for tissue-targeted delivery of negatively charged biomolecules (siRNA/miRNA, mRNA, plasmid DNA, small proteins, etc).
  • Altogen Biosystems announced that its Nanoparticle-basedIn VivoTransfection Reagent was used for effective overcoming blood-brain barrier and successful transfection of glioblastoma tumor cells with both plasmid DNA and siRNA molecules.
  • Altogen's nanoparticle in vivo transfection reagent was referenced in over 40 research publications for effective in vivo delivery of biomolecules, however Altogen scientists still had to develop modified in vivo transfection protocol to enable brain-targeted delivery.

Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe

Retrieved on: 
Thursday, July 22, 2021
Nucleic acids, RNA, Branches of biology, Molecular biology, Biotechnology, RNA vaccine, RNA therapeutics, Small interfering RNA, Sense, Sirna, Messenger RNA, Arcturus Therapeutics

SANTA CLARA, Calif., July 22, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global RNA Therapeutics: Technology Growth Opportunities, reveals that ribonucleic acid (RNA) therapeutics is poised to gain momentum in the next few years and can potentially be applied to a wide variety of disease interventions. Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D). 

Key Points: 
  • Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D).
  • As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies."
  • Hence, RNA therapeutics investment has a better chance of commercial success and enables better returns in less time for market participants.
  • mRNA vaccines and active participation of big pharmaceutical companies: Currently, RNA therapeutics is one of the fastest and most promising approaches in biological therapeutics.

Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe

Retrieved on: 
Thursday, July 22, 2021
Nucleic acids, RNA, Branches of biology, Molecular biology, Biotechnology, RNA vaccine, RNA therapeutics, Small interfering RNA, Sense, Sirna, Messenger RNA, Arcturus Therapeutics

SANTA CLARA, Calif., July 22, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global RNA Therapeutics: Technology Growth Opportunities, reveals that ribonucleic acid (RNA) therapeutics is poised to gain momentum in the next few years and can potentially be applied to a wide variety of disease interventions. Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D). 

Key Points: 
  • Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D).
  • As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies."
  • Hence, RNA therapeutics investment has a better chance of commercial success and enables better returns in less time for market participants.
  • mRNA vaccines and active participation of big pharmaceutical companies: Currently, RNA therapeutics is one of the fastest and most promising approaches in biological therapeutics.

Global RNA Therapeutics 2021 Market - Technology Growth Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Biotechnology, Pharmaceutical, Health, Nucleic acids, Branches of biology, RNA, RNA therapeutics, RNA interference, RNA silencing, Small interfering RNA

The "RNA Therapeutics: Global Technology Growth Opportunities, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RNA Therapeutics: Global Technology Growth Opportunities, 2021" report has been added to ResearchAndMarkets.com's offering.
  • The fundamentals of RNA therapeutics consists of delivering functional RNA at a target; however, this is restricted due to its fragile nature and lack of appropriate delivery systems.
  • This research is intended to answer the following questions:
    What are the driving factors for RNA therapeutics?
  • Despite a wide variety, messenger RNA therapeutics and RNA interference are the most widely studied approaches among RNA therapeutics.

Sirnaomics Receives FDA Approval of IND for Phase 1 Clinical Trial of Systemic RNAi Therapeutic STP707 for Solid Tumor Treatment

Retrieved on: 
Tuesday, July 6, 2021
RNA, Branches of biology, Biology, Molecular biology, Biochemistry, Gene expression, Small interfering RNA, RNA interference, Sirna Therapeutics, RNA therapeutics, Sirna, Arcturus Therapeutics

Sirnaomics' lead product candidate, STP707, is an anti-cancer siRNA (small interfering RNA) therapeutic.

Key Points: 
  • Sirnaomics' lead product candidate, STP707, is an anti-cancer siRNA (small interfering RNA) therapeutic.
  • "The IND green light from the U.S. FDA for Sirnaomics' first IV oncology drug, STP707, represents another major milestone for the company's mission in discovery and development of novel siRNA therapeutics for unmet clinical needs.
  • "Sirnaomics is currently in a strong position to lead the RNAi community in the development of novel oncology therapeutics."
  • "This IND approval represents a very important moment for the company as we can now expand our therapeutic reach in IV administration.

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Retrieved on: 
Tuesday, July 6, 2021
Health, Infectious diseases, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Nucleic acids, Branches of biology, RNA, Molecular biology, Gene expression, Biotechnology, Arcturus Therapeutics, RNA therapeutics, Small interfering RNA, Sense, Arcturus COVID-19 vaccine, RNA vaccine

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor and scientific conferences.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor and scientific conferences.
  • Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (222 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).